Martin AS, Monsour M, Kissin DM, et al. Trends in severe maternal morbidity after assisted reproductive technology in the United States, 2008–2012. Obstet Gynecol. 2016;127(1):59–66.
Pepine CJ, Park K. Fertility therapy and long-term cardiovascular risk: raising more questions than answers? J Am Coll Cardiol. 2017;70(10):1214–5.
Moran LJ, Misso ML, Wild RA, et al. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2010;16(4):347–63.
Sirmans SM, Parish RC, Blake S, et al. Epidemiology and comorbidities of polycystic ovary syndrome in an indigent population. J Investig Med. 2014;62(6):868–74.
Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med. 2001;111(8):607–13.
Vgontzas AN, Legro RS, Bixler EO, et al. Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness: role of insulin resistance. J Clin Endocrinol Metab. 2001;86(2):517–20.
Chang AY, Oshiro J, Ayers C, et al. Influence of race/ethnicity on cardiovascular risk factors in polycystic ovary syndrome, the Dallas Heart Study. Clin Endocrinol. 2016;85(1):92–9.
Boulman N, Levy Y, Leiba R, et al. Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab. 2004;89(5):2160–5.
Talbott EO, Guzick DS, Sutton-Tyrrell K, et al. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol. 2000;20(11):2414–21.
Hu FB, Grodstein F, Hennekens CH, et al. Age at natural menopause and risk of cardiovascular disease. Arch Intern Med. 1999;159(10):1061–6.
Jacobsen BK, Knutsen SF, Fraser GE. Age at natural menopause and total mortality and mortality from ischemic heart disease: the Adventist Health Study. J Clin Epidemiol. 1999;52(4):303–7.
Snowdon DA. Early natural menopause and the duration of postmenopausal life. Findings from a mathematical model of life expectancy. J Am Geriatr Soc. 1990;38(4):402–8.
Snowdon DA, Kane RL, Beeson WL, et al. Is early natural menopause a biologic marker of health and aging? Am J Public Health. 1989;79(6):709–14.
Kalantaridou SN, Naka KK, Papanikolaou E, et al. Impaired endothelial function in young women with premature ovarian failure: normalization with hormone therapy. J Clin Endocrinol Metab. 2004;89(8):3907–13.
Cooper GS, Sandler DP. Age at natural menopause and mortality. Ann Epidemiol. 1998;8(4):229–35.
van der Schouw YT, van der Graaf Y, Steyerberg EW, et al. Age at menopause as a risk factor for cardiovascular mortality. Lancet. 1996;347(9003):714–8.
Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–33.
Langrish JP, Mills NL, Bath LE, et al. Cardiovascular effects of physiological and standard sex steroid replacement regimens in premature ovarian failure. Hypertension. 2009;53(5):805–11.
Mu F, Rich-Edwards J, Rimm EB, et al. Endometriosis and risk of coronary heart disease. Circ Cardiovasc Qual Outcomes. 2016;9(3):257–64.
Gunby J, Bissonnette F, Librach C, et al. Assisted reproductive technologies (ART) in Canada: 2007 results from the Canadian ART Register. Fertil Steril. 2011;95(2):542–547.e541–510.
Talaulikar VS, Arulkumaran S. Reproductive outcomes after assisted conception. Obstet Gynecol Surv. 2012;67(9):566–83.
Belanoff C, Declercq ER, Diop H, et al. Severe maternal morbidity and the use of assisted reproductive technology in Massachusetts. Obstet Gynecol. 2016;127(3):527–34.
Wang ET, Ozimek JA, Greene N, et al. Impact of fertility treatment on severe maternal morbidity. Fertil Steril. 2016;106(2):423–6.
Söderström-Anttila V, Tiitinen A, Foudila T, et al. Obstetric and perinatal outcome after oocyte donation: comparison with in-vitro fertilization pregnancies. Hum Reprod. 1998;13(2):483–90.
Wiggins DA, Main E. Outcomes of pregnancies achieved by donor egg in vitro fertilization—a comparison with standard in vitro fertilization pregnancies. Am J Obstet Gynecol. 2005;192(6):2002–6. discussion 2006–2008
Udell JA, Lu H, Redelmeier DA. Long-term cardiovascular risk in women prescribed fertility therapy. J Am Coll Cardiol. 2013;62(18):1704–12.
Ben-Yaakov RD, Kessous R, Shoham-Vardi I, et al. Fertility treatments in women who become pregnant and carried to viability, and the risk for long-term maternal cardiovascular morbidity. Am J Perinatol. 2016;33(14):1388–93.
Nastri CO, Ferriani RA, Rocha IA, et al. Ovarian hyperstimulation syndrome: pathophysiology and prevention. J Assist Reprod Genet. 2010;27(2–3):121–8.
Ceelen M, van Weissenbruch MM, Vermeiden JP, et al. Cardiometabolic differences in children born after in vitro fertilization: follow-up study. J Clin Endocrinol Metab. 2008;93(5):1682–8.
Scherrer U, Rimoldi SF, Rexhaj E, et al. Systemic and pulmonary vascular dysfunction in children conceived by assisted reproductive technologies. Circulation. 2012;125(15):1890–6.
Valenzuela-Alcaraz B, Crispi F, Bijnens B, et al. Assisted reproductive technologies are associated with cardiovascular remodeling in utero that persists postnatally. Circulation. 2013;128(13):1442–50.
Xu GF, Zhang JY, Pan HT, et al. Cardiovascular dysfunction in offspring of ovarian-hyperstimulated women and effects of estradiol and progesterone: a retrospective cohort study and proteomics analysis. J Clin Endocrinol Metab. 2014;99(12):E2494–503.
Reynolds LP, Borowicz PP, Palmieri C, et al. Placental vascular defects in compromised pregnancies: effects of assisted reproductive technologies and other maternal stressors. Adv Exp Med Biol. 2014;814:193–204.
Roos-Hesselink JW, Johnson MR. Does fertility therapy hamper cardiovascular outcome? J Am Coll Cardiol. 2013;62(18):1713–4.
Udell JA, Lu H, Redelmeier DA. Failure of fertility therapy and subsequent adverse cardiovascular events. CMAJ. 2017;189(10):E391–7.
Parikh NI, Cnattingius S, Mittleman MA, et al. Subfertility and risk of later life maternal cardiovascular disease. Hum Reprod. 2012;27(2):568–75.
Binder H, Dittrich R, Einhaus F, et al. Update on ovarian hyperstimulation syndrome: part 1—incidence and pathogenesis. Int J Fertil Womens Med. 2007;52(1):11–26.
Gonçalves PB, Ferreira R, Gasperin B, et al. Role of angiotensin in ovarian follicular development and ovulation in mammals: a review of recent advances. Reproduction. 2012;143(1):11–20.
Hassan E, Creatsas G, Mastorakos G, et al. Clinical implications of the ovarian/endometrial renin-angiotensin-aldosterone system. Ann N Y Acad Sci. 2000;900:107–18.
Henriksson P, Westerlund E, Wallén H, et al. Incidence of pulmonary and venous thromboembolism in pregnancies after in vitro fertilisation: cross sectional study. BMJ. 2013;346:e8632.
Morris RS, Paulson RJ. Increased angiotensin-converting enzyme activity in a patient with severe ovarian hyperstimulation syndrome. Fertil Steril. 1999;71(3):562–3.
Vloeberghs V, Peeraer K, Pexsters A, et al. Ovarian hyperstimulation syndrome and complications of ART. Best Pract Res Clin Obstet Gynaecol. 2009;23(5):691–709.
Oliver-Williams CT, Heydon EE, Smith GC, et al. Miscarriage and future maternal cardiovascular disease: a systematic review and meta-analysis. Heart. 2013;99(22):1636–44.
Parker DR, Lu B, Sands-Lincoln M, et al. Risk of cardiovascular disease among postmenopausal women with prior pregnancy loss: the women’s health initiative. Ann Fam Med. 2014;12(4):302–9.
Lawlor DA, Emberson JR, Ebrahim S, et al. Is the association between parity and coronary heart disease due to biological effects of pregnancy or adverse lifestyle risk factors associated with child-rearing? Findings from the British Women’s Heart and Health Study and the British Regional Heart Study. Circulation. 2003;107(9):1260–4.
Ness RB, Harris T, Cobb J, et al. Number of pregnancies and the subsequent risk of cardiovascular disease. N Engl J Med. 1993;328(21):1528–33.
Parikh NI, Cnattingius S, Dickman PW, et al. Parity and risk of later-life maternal cardiovascular disease. Am Heart J. 2010;159(2):215–221.e216.